We speculate that one potentially protective mechanism for patients with DM and/or SLE is the use of TLR7 inhibitory anti-rheumatic therapies such as antimalarial therapies (e.g., hydroxychloroquine or chloroquine). This evidence concerns the gene TLR7 and systemic lupus erythematosus.